Different Strategies Targeting Gut Microbiota for the Management of Several Disorders: A Sustainable Approach


Дәйексөз келтіру

Толық мәтін

Аннотация

Background::A potential limelight is flashed on the Gut Microbiota (GM) in the human body, which confers additional psychological as well as physiological attributes to health. Other than just occupying a wide portion of the gastrointestinal tract, it also plays numerous functions in the systems of the body. Gut Microbiota is largely responsible for a considerably vast array of conditions such as obesity, diabetes ,other metabolic disorders, and cardiovascular disorders. Strategies targeting the gut microbiota have been proposed as a promising approach for the management of these disorders.

Objective::This review aims to summarize the different strategies targeting the gut microbiota for the management of several disorders and to highlight the importance of a sustainable approach.

Methods::A comprehensive literature search was conducted using various databases between 2008 and 2022 that focused on the use of prebiotics, probiotics, synbiotics, postbiotics, fecal microbiota transplantation, dietary interventions, and antibiotics.

Results::Different strategies targeting the gut microbiota for the management of several disorders were identified, including probiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, and dietary interventions. Modification in diet and lifestyle, allowing favorable microbiota growth in the stomach, intake of prebiotics and probiotics, and fecal microbiota transplantation are amongst the widely accepted recent approaches allowing the application of GM in the field of treatment.

Conclusion::Although considerable steps in enhancing and understanding the mechanism of treatment with the help of gut microbiota are under progress, much diversified and elaborate research must be conducted in order to enhance and implement the use of GM with high effectiveness.

Авторлар туралы

Mahima Chowdhury

School of Pharmaceutical Sciences, Lovely Professional University

Email: info@benthamscience.net

Neil Raj Chaudhary

School of Pharmaceutical Sciences, Lovely Professional University

Email: info@benthamscience.net

Paranjeet Kaur

Chitkara College of Pharmacy, Chitkara University

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Anju Goyal

Chitkara College of Pharmacy, Chitkara University

Email: info@benthamscience.net

Sanjeev Sahu

School of Pharmaceutical Sciences, Lovely Professional University

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ 2018; 361: k2179. doi: 10.1136/bmj.k2179 PMID: 29899036
  2. Choices EFH. What is the role of gut bacteria in human health? EUFIC 2013. Available from: https://www.eufic.org/en/healthy-living/article/the-role-of-gut-microorganisms-in-human-health (Accessed on 25-08-2022).
  3. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015; 21(29): 8787-803. doi: 10.3748/wjg.v21.i29.8787 PMID: 26269668
  4. Zhang S, Cai Y, Meng C, et al. The role of the microbiome in diabetes mellitus. diabetes research and clinical practice 2021; 172: 108645.
  5. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31(1): 69-75. doi: 10.1097/MOG.0000000000000139 PMID: 25394236
  6. Fredricks D N. The human microbiota: How microbial communities affect health and disease. 2013. doi: 10.1002/9781118409855
  7. Seekatz AM, Aas J, Gessert CE, et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio 2014; 5(3): e00893-14. doi: 10.1128/mBio.00893-14 PMID: 24939885
  8. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology EBioMedicine. Elsevier BV 2020.
  9. Novakovic M, Rout A, Kingsley T, et al. Role of gut microbiota in cardiovascular diseases. World J Cardiol 2020; 12(4): 110-22. doi: 10.4330/wjc.v12.i4.110 PMID: 32431782
  10. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28(2): 203-9. PMID: 25830558
  11. Liao DH, Zhao JB, Gregersen H. Gastrointestinal tract modelling in health and disease. World J Gastroenterol 2009; 15(2): 169-76. doi: 10.3748/wjg.15.169 PMID: 19132766
  12. Cheng LK, O’Grady G, Du P, Egbuji JU, Windsor JA, Pullan AJ. Gastrointestinal system. Wiley Interdiscip Rev Syst Biol Med 2010; 2(1): 65-79. doi: 10.1002/wsbm.19 PMID: 20836011
  13. Jovel J, Dieleman LA, Kao D, Mason AL, Wine E. The human gut microbiome in health and disease. Metagenomics 2018; 197-213.
  14. Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol 2021; 11: 625913. doi: 10.3389/fcimb.2021.625913 PMID: 33816335
  15. Sun P, Su L, Zhu H, et al. Gut microbiota regulation and their implication in the development of neurodegenerative disease. Microorganisms 2021; 9(11): 2281. doi: 10.3390/microorganisms9112281 PMID: 34835406
  16. Zhang H, Chen Y, Wang Z, et al. Implications of gut microbiota in neurodegenerative diseases. Front Immunol 2022; 13: 785644. doi: 10.3389/fimmu.2022.785644 PMID: 35237258
  17. Nagao-Kitamoto H, Kitamoto S, Kuffa P, Kamada N. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest Res 2016; 14(2): 127-38. doi: 10.5217/ir.2016.14.2.127 PMID: 27175113
  18. Yan Q, Gu Y, Li X, et al. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol 2017; 7: 381. doi: 10.3389/fcimb.2017.00381 PMID: 28884091
  19. Jayasinghe TN, Chiavaroli V, Holland DJ, Cutfield WS, O’Sullivan JM. The new era of treatment for obesity and metabolic disorders: Evidence and expectations for gut microbiome transplantation. Front Cell Infect Microbiol 2016; 6: 15. doi: 10.3389/fcimb.2016.00015 PMID: 26925392
  20. Lim YY, Lee YS, Ooi DSQ. Engineering the gut microbiome for treatment of obesity: A review of current understanding and progress. Biotechnol J 2020; 15(10): 2000013. doi: 10.1002/biot.202000013 PMID: 32663372
  21. Muscogiuri G, Cantone E, Cassarano S, et al. on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: A new path to treat obesity. Int J Obes Suppl 2019; 9(1): 10-9. doi: 10.1038/s41367-019-0011-7 PMID: 31391921
  22. Jiang H, Cai M, Shen B, Wang Q, Zhang T, Zhou X. Synbiotics and gut microbiota: New perspectives in the treatment of type 2 diabetes mellitus. Foods 2022; 11(16): 2438. doi: 10.3390/foods11162438 PMID: 36010438
  23. Zhang L, Chu J, Hao W, et al. Gut microbiota and type 2 diabetes mellitus: Association, mechanism, and translational applications. Mediators of Inflammation 2021; 2021
  24. Andrade S, Borges N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Res 2009; 76(4): 469-74. doi: 10.1017/S0022029909990173 PMID: 19825213
  25. Varesi A, Pierella E, Romeo M, et al. The potential role of gut microbiota in Alzheimer’s disease: From diagnosis to treatment. Nutrients 2022; 14(3): 668. doi: 10.3390/nu14030668 PMID: 35277027
  26. Nishikawa M, Brickman AM, Manly JJ, Schupf N, Mayeux RP, Gu Y. Dietary prebiotic consumption is associated with reduced risk of Alzheimer’s disease in a multiethnic population. Curr Alzheimer Res 2021; 18(12): 984. doi: 10.2174/1567205019666211222115142 PMID: 34951365
  27. Barbosa RSD, Vieira-Coelho MA. Probiotics and prebiotics: Focus on psychiatric disorders: A systematic review. Nutr Rev 2020; 78(6): 437-50. doi: 10.1093/nutrit/nuz080 PMID: 31769847
  28. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science 1965; 147(3659): 747-8. doi: 10.1126/science.147.3659.747 PMID: 14242024
  29. Martinowich K, Lu B. Interaction between BDNF and serotonin: Role in mood disorders. Neuropsychopharmacology 2008; 33(1): 73-83. doi: 10.1038/sj.npp.1301571 PMID: 17882234
  30. Agahi A, Hamidi GA, Daneshvar R, et al. Does severity of Alzheimer’s disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol 2018; 9: 662. doi: 10.3389/fneur.2018.00662 PMID: 30158897
  31. Masino SA, Rho JM. Mechanisms of ketogenic diet action. Epilepsia 2010; 51(s5): 85-5. doi: 10.1111/j.1528-1167.2010.02871.x
  32. Bostock ECS, Kirkby KC, Taylor BVM. The current status of the ketogenic diet in psychiatry. Front Psychiatry 2017; 8: 43. doi: 10.3389/fpsyt.2017.00043 PMID: 28373848
  33. Zhu M, Liu X, Ye Y, et al. Gut Microbiota: A novel therapeutic target for Parkinson’s disease. Front Immunol 2022; 13: 937555. doi: 10.3389/fimmu.2022.937555 PMID: 35812394
  34. Georgescu D, Ancusa O, Georgescu L, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: Is there hope? Clin Interv Aging 2016; 11: 1601-8. doi: 10.2147/CIA.S106284 PMID: 27956826
  35. Liu X, Du ZR, Wang X, et al. Polymannuronic acid prebiotic plus Lacticaseibacillus rhamnosus GG probiotic as a novel synbiotic promoted their separate neuroprotection against Parkinson’s disease. Food Res Int 2022; 155: 111067. doi: 10.1016/j.foodres.2022.111067 PMID: 35400445
  36. Chen ZJ, Liang CY, Yang LQ, et al. Association of Parkinson’s disease with microbes and microbiological therapy. Front Cell Infect Microbiol 2021; 11: 619354. doi: 10.3389/fcimb.2021.619354 PMID: 33763383
  37. Barichella M, Cereda E, Cassani E, et al. Dietary habits and neurological features of Parkinson’s disease patients: Implications for practice. Clin Nutr 2017; 36(4): 1054-61. doi: 10.1016/j.clnu.2016.06.020 PMID: 27406858
  38. Kraeuter A-K, Guest P C, Sarnyai Z. The therapeutic potential of ketogenic diet throughout life: Focus on metabolic, neurodevelopmental and neurodegenerative disorders. Reviews on Biomarker Studies in Aging and Anti-Aging Research 2019; 77-101.
  39. Bayliss JA, Lemus MB, Stark R, et al. Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson’s disease. J Neurosci 2016; 36(10): 3049-63. doi: 10.1523/JNEUROSCI.4373-15.2016 PMID: 26961958
  40. Fu W, Zhuang W, Zhou S, Wang X. Plant-derived neuroprotective agents in Parkinson’s disease. Am J Transl Res 2015; 7(7): 1189-202. PMID: 26328004
  41. Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol Sci 2015; 16(12): 7493-519. doi: 10.3390/ijms16047493 PMID: 25849657
  42. Tsoi H, Chu ES, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017; 152(6): 1419-33. doi: 10.1053/j.gastro.2017.01.009
  43. Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 2017; 153(6): 1621-33. doi: 10.1053/j.gastro.2017.08.022

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024